In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
Unafraid of a headache or a belly rumble, advocates maintain that glutathione helps combat age-related changes by stimulating the repair of damaged tissue and promoting the production of new, healthy cells
KOJIC ACID
Chronic DVT When documentation reads DVT without temporal qualification, query the provider: Based on imaging findings and clinical presentation, does this represent (a) acute DVT, (b) chronic DVT, or (c) acute-on-chronic DVT? The acute vs
Scientists from the WHO recently wrote: The approval of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of obesity creates potential for a transformation of the whole health system that could halt and reverse the global obesity pandemic through prevention and effective integrated management. Growing crisis South Africa is grappling with dual diabetes and obesity epidemics, on top of the HIV and TB epidemics, but is not responding effectively, resulting in high obesity and diabetes-related deaths
